Rubius Therapeutics, Inc. (RUBY)

NASDAQ: RUBY · IEX Real-Time Price · USD
0.210
-0.003 (-1.50%)
At close: Dec 2, 2022 4:00 PM
0.219
+0.009 (4.29%)
After-hours: Dec 2, 2022 7:56 PM EST
-1.5%
Market Cap 19.24M
Revenue (ttm) n/a
Net Income (ttm) -214.55M
Shares Out 90.36M
EPS (ttm) -2.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 599,372
Open 0.22
Previous Close 0.213
Day's Range 0.2 - 0.231
52-Week Range 0.2 - 13.52
Beta 2.43
Analysts Sell
Price Target 10.71 (+5,004.9%)
Earnings Date Nov 14, 2022

About RUBY

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts. [Read more]

Industry Biotechnology
IPO Date Jul 18, 2018
CEO Pablo Cagnoni
Employees 9
Stock Exchange NASDAQ
Ticker Symbol RUBY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for RUBY stock is "Sell." The 12-month stock price forecast is 10.71, which is an increase of 5,004.86% from the latest price.

Price Target
$10.71
(5,004.86% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes

Dannielle Appelhans to Become President and Chief Executive Officer

1 month ago - GlobeNewsWire

Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference

CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell ...

2 months ago - GlobeNewsWire

Rubius Therapeutics Announces Strategic Update

Company to Focus on Advancing Next Generation Red Blood Cell-Based Cell Conjugation Platform

2 months ago - GlobeNewsWire

Rubius Therapeutics to Provide Strategic Update

Investor Teleconference and Webcast Scheduled Tomorrow, September 13, 2022, at 7:30 a.m. EDT Investor Teleconference and Webcast Scheduled Tomorrow, September 13, 2022, at 7:30 a.m. EDT

2 months ago - GlobeNewsWire

Rubius Therapeutics, Inc. (RUBY) Upgraded to Buy: What Does It Mean for the Stock?

Rubius Therapeutics, Inc. (RUBY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 months ago - Zacks Investment Research

Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

New Preclinical Data Presented at the FOCIS 2022 Annual Meeting Demonstrating Prevention of Type 1 Diabetes in a Stringent Preclinical Model

3 months ago - GlobeNewsWire

Rubius Therapeutics to Announce Second Quarter 2022 Financial Results

CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an ent...

4 months ago - GlobeNewsWire

HotSpot Therapeutics Appoints Jose Carmona to Board of Directors

BOSTON, July 19, 2022 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and ...

4 months ago - PRNewsWire

Rubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directors

CAMBRIDGE, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an ent...

4 months ago - GlobeNewsWire

Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical ...

Prevention of Type 1 Diabetes in a Stringent Preclinical Model from Ongoing Experiment;Two Antigens Prevent Disease Driven by Many Autoantigens Demonstrating Bystander Suppression

5 months ago - GlobeNewsWire

Rubius Therapeutics to Present at the Jefferies Global Healthcare Conference

CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an ent...

6 months ago - GlobeNewsWire

Rubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanc...

CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entire...

6 months ago - GlobeNewsWire

Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors

CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an enti...

6 months ago - GlobeNewsWire

Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Presented Updated Clinical Data from Monotherapy Phase 1 Arm of RTX-240 Clinical Trial in Advanced Solid Tumors, Showing Clinical Responses with Favorable Tolerability in PD-(L)1 Refractory Disease

6 months ago - GlobeNewsWire

Rubius Therapeutics to Announce First Quarter 2022 Financial Results

CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an en...

7 months ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rubius Therapeutics, Inc. - RUBY

NEW YORK , April 23, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rubius Therapeutics, Inc. ("Rubius" or the "Company") (NASDAQ: RUBY).  Such investors are advise...

7 months ago - PRNewsWire

Rubius Shares Plunge After Early Data From RTX-240 Solid Tumor Trial

Rubius Therapeutics Inc (NASDAQ: RUBY) has announced updated data from the ongoing monotherapy Phase 1 arm of the Phase 1/2 trial of RTX-240 in advanced solid tumors. Data were shared at the American As...

7 months ago - Benzinga

Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 C...

Best Responses Include Partial Responses in Certain Patients with Non-Small Cell Lung Cancer, Metastatic Anal Cancer and Metastatic Uveal Melanoma with No Treatment-Related Grade 3/4 Adverse Events or D...

7 months ago - GlobeNewsWire

Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Ph...

CAMBRIDGE, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an en...

7 months ago - GlobeNewsWire

Rubius Therapeutics to Present Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 at the American As...

Updated Results from Single-Agent Phase 1 Clinical Trial of RTX-240 in Advanced Solid Tumors to be Presented in a Poster at the American Association of Cancer Research Annual Meeting on Tuesday, April 1...

8 months ago - GlobeNewsWire

Rubius Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

First Patient Dosed in Phase 1/2 Clinical Trial of RTX-224 in Patients with Certain Advanced Solid Tumors in January 2022 Single-Agent Phase 1 RTX-240 Clinical Trial in Advanced Solid Tumors Continues w...

9 months ago - GlobeNewsWire

Rubius Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results

CAMBRIDGE, Mass., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an ent...

9 months ago - GlobeNewsWire

Rubius Therapeutics to Present at the Virtual Guggenheim Healthcare Talks and SVB Leerink Global Healthcare Conferenc...

CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an ent...

10 months ago - GlobeNewsWire

Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-224, a Broad Immune Agonist, for the ...

CAMBRIDGE, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an ent...

10 months ago - GlobeNewsWire

Rubius Therapeutics Recaps 2021 Achievements and Outlines 2022 Objectives Across the RED PLATFORM at the 40th Annual ...

Continuing Dose Escalation in Single-Agent Phase 1 RTX-240 Clinical Trial in Advanced Solid Tumors with No Dose-Limiting Toxicities Observed to Date and an NK Cell Dose Response with Clinical Results Ex...

10 months ago - GlobeNewsWire